Kodiak Sciences Research Note: Clinical De-Risking Meets a Demanding Valuation
Kodiak Sciences has reduced clinical uncertainty, but filing execution, regulatory review and capital demands now carry more of the evidence burden.
Kodiak Sciences has reduced clinical uncertainty, but filing execution, regulatory review and capital demands now carry more of the evidence burden.
FormFactor’s growth, margin recovery and cash generation are improving, while a sharp share advance raises the evidence required for durability.
Kodiak Sciences cleared an important Phase 3 hurdle, while its filing plan and sharp repricing make regulatory execution the central question.
Applied Digital’s contracted footprint is substantial, but recurring rent, campus delivery and funding clarity will decide the quality of conversion.
FormFactor has paired faster growth with a sharp margin recovery, while the October 1 market price already discounts substantial continuation.
APLD Premium research.
Minneapolis Fed President Neel Kashkari said further rate increases may be needed into 2027, extending the policy constraint behind the published market thesis.
Stocks ended modestly higher after a rough trip through the bond market.
Select Water Solutions pairs Pilot’s long-duration contracts with a cash-heavy deal, leaving financing and integration as the evidence test.
WTTR Premium research.